Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxytocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 12/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 6/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 5/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytocin SCHEMBL1173243 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL14085374 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL16373316 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL8370159 | 1.00 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL2126148 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL5110121 | 0.98 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B | |
| Oxytocin SCHEMBL1661474 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B | |
| SCHEMBL19303330 | 0.98 | OXTR (0.96) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383490-B2 | Generic high-capacity protein capture and tunable electrochemical release | NYCTEA TECHNOLOGIES AB (SE) | 2025-08-12 | — | — | US | disclosed |
| EP-4543415-A1 | OXYTOCIN FORMULATION | Hikma Pharmaceuticals USA Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4065509-B1 | GENERIC HIGH-CAPACITY PROTEIN CAPTURE AND TUNABLE ELECTROCHEMICAL RELEASE | NYCTEA TECH AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| US-20240139278-A1 | OXYTOCIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2024-05-02 | — | — | US | disclosed |
| WO-2023247760-A1 | OXYTOCIN FORMULATION | XELLIA PHARMACEUTICALS APS (DK) | 2023-12-28 | — | — | WO | disclosed |
| US-20220409726-A1 | GENERIC HIGH-CAPACITY PROTEIN CAPTURE AND TUNABLE ELECTROCHEMICAL RELEASE | NYCTEA TECHNOLOGIES AB (SE) | 2022-12-29 | — | — | US | disclosed |
| EP-4096690-A1 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | 4D Pharma Research Limited (GB) | 2022-12-07 | — | — | EP | disclosed |
| EP-4065509-A1 | GENERIC HIGH-CAPACITY PROTEIN CAPTURE AND TUNABLE ELECTROCHEMICAL RELEASE | Nyctea Technologies AB (SE) | 2022-10-05 | — | — | EP | disclosed |
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-02-03 | — | — | US | disclosed |
| EP-3438121-B1 | LIQUID PHASE SYNTHESIS METHOD FOR OXYTOCIN USING POLYPEPTIDES | LANZHOU KAIBO PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| EP-3438121-A1 | LIQUID PHASE SYNTHESIS METHOD FOR OXYTOCIN USING POLYPEPTIDES | Lanzhou Kaibo Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139278-A1 | OXYTOCIN FORMULATION | OXTR, AVPR2, AVPR1B | OXTR 1/4885AVPR1A 4/4885AVPR2 2/4885 |
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | PLOD2, TPSB2, PLOD1 | OXTR 3279/4885AVPR1A 2821/4885AVPR2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.